Cognition Therapeutics’ (CGTX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a report published on Thursday,Benzinga reports. Chardan Capital currently has a $11.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Cognition Therapeutics in a research report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.30.

Cognition Therapeutics Trading Down 0.6 %

Cognition Therapeutics stock opened at $0.63 on Thursday. The firm has a market cap of $26.18 million, a PE ratio of -0.65 and a beta of 1.26. The stock’s 50 day simple moving average is $0.48 and its two-hundred day simple moving average is $0.92. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CGTX. CM Management LLC raised its position in Cognition Therapeutics by 14.3% during the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the period. Sigma Planning Corp raised its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Cognition Therapeutics in the 3rd quarter valued at about $27,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.